Literature DB >> 20422337

Epidermal growth factor protects the heart against low-flow ischemia-induced injury.

J Lorita1, M Soley, I Ramírez.   

Abstract

The role of ErbB4 and ErbB2 in the heart of adult mammals is well established. The heart also expresses ErbB1 (the epidermal growth factor (EGF) receptor), but this receptor has received less attention. We studied the effect of EGF on the response of isolated mouse heart to low-flow ischemia and reperfusion. Reducing perfusate flow to 10% for 30 min resulted in an increase in anaerobic metabolism and the leakage of lactate dehydrogenase during reperfusion. In addition, left ventricle +dP/dt and developed pressure were depressed (20-25%) during reperfusion. The addition of EGF 5 min before and throughout the ischemic period prevented the increase in anaerobic metabolism and the leakage of intracellular lactate dehydrogenase during reperfusion. EGF improved both +dP/dt and developed pressure during ischemia and prevented the decrease in dP/dt during reperfusion. To determine whether the effect of EGF on cell integrity depends on its effect on contractility, we studied nonbeating isolated myocytes. In these cells, anoxia and reoxygenation reduced cell viability by nearly 25%. EGF prevented such a decrease. Our results indicate that, like ErbB4 and ErbB2, ErbB1 also has an important role in the heart of adult animals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20422337     DOI: 10.1007/s13105-010-0009-7

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  36 in total

Review 1.  Prime causes of rapid cardiomyocyte death during reperfusion.

Authors:  H M Piper; D García-Dorado
Journal:  Ann Thorac Surg       Date:  1999-11       Impact factor: 4.330

2.  Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes.

Authors:  Y Y Zhao; D R Sawyer; R R Baliga; D J Opel; X Han; M A Marchionni; R A Kelly
Journal:  J Biol Chem       Date:  1998-04-24       Impact factor: 5.157

3.  Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy.

Authors:  Xifu Liu; Xinhua Gu; Zhaoming Li; Xinyan Li; Hui Li; Jianjie Chang; Ping Chen; Jing Jin; Bing Xi; Denghong Chen; Donna Lai; Robert M Graham; Mingdong Zhou
Journal:  J Am Coll Cardiol       Date:  2006-09-14       Impact factor: 24.094

4.  Declines in mitochondrial respiration during cardiac reperfusion: age-dependent inactivation of alpha-ketoglutarate dehydrogenase.

Authors:  D T Lucas; L I Szweda
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 5.  ErbB and HB-EGF signaling in heart development and function.

Authors:  Ryo Iwamoto; Eisuke Mekada
Journal:  Cell Struct Funct       Date:  2006       Impact factor: 2.212

6.  Localizing extracellular signal-regulated kinase (ERK) in pharmacological preconditioning's trigger pathway.

Authors:  Sebastian Philipp; Stuart D Critz; Lin Cui; Viktoriya Solodushko; Michael V Cohen; James M Downey
Journal:  Basic Res Cardiol       Date:  2005-11-11       Impact factor: 17.165

7.  Regulation of voltage-gated cardiac sodium current by epidermal growth factor receptor kinase in guinea pig ventricular myocytes.

Authors:  Hui Liu; Hai-Ying Sun; Chu-Pak Lau; Gui-Rong Li
Journal:  J Mol Cell Cardiol       Date:  2006-12-22       Impact factor: 5.000

8.  A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats.

Authors:  H Ueda; T Nakamura; K Matsumoto; Y Sawa; H Matsuda; T Nakamura
Journal:  Cardiovasc Res       Date:  2001-07       Impact factor: 10.787

9.  Basic FGF reduces stunning via a NOS2-dependent pathway in coronary-perfused mouse hearts.

Authors:  T G Hampton; I Amende; J Fong; V E Laubach; J Li; C Metais; M Simons
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-07       Impact factor: 4.733

10.  Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction.

Authors:  Viswanathan Rajagopalan; Irving H Zucker; Jocelyn A Jones; Michaela Carlson; Ying J Ma
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-03       Impact factor: 4.733

View more
  6 in total

1.  EGF is required for cardiac differentiation of P19CL6 cells through interaction with GATA-4 in a time- and dose-dependent manner.

Authors:  Cai-Xia Ma; Yang-Liu Song; Liyun Xiao; Li-Xiang Xue; Wen-Juan Li; Brigitte Laforest; Hiba Komati; Wei-Ping Wang; Zhu-Qing Jia; Chun-Yan Zhou; Yunzeng Zou; Mona Nemer; Shan-Feng Zhang; Xiaowen Bai; Huijian Wu; Ming-Xi Zang
Journal:  Cell Mol Life Sci       Date:  2014-12-14       Impact factor: 9.261

2.  Transplantation of autologously derived mitochondria protects the heart from ischemia-reperfusion injury.

Authors:  Akihiro Masuzawa; Kendra M Black; Christina A Pacak; Maria Ericsson; Reanne J Barnett; Ciara Drumm; Pankaj Seth; Donald B Bloch; Sidney Levitsky; Douglas B Cowan; James D McCully
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-01-25       Impact factor: 4.733

Review 3.  Epidermal growth factor, from gene organization to bedside.

Authors:  Fenghua Zeng; Raymond C Harris
Journal:  Semin Cell Dev Biol       Date:  2014-02-07       Impact factor: 7.727

4.  Gene Expression Analyses during Spontaneous Reversal of Cardiomyopathy in Mice with Repressed Nuclear CUG-BP, Elav-Like Family (CELF) Activity in Heart Muscle.

Authors:  Twishasri Dasgupta; Ryan J Coram; Samantha J Stillwagon; Andrea N Ladd
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

Review 5.  Pharmacological Protection against Ischemia-Reperfusion Injury by Regulating the Nrf2-Keap1-ARE Signaling Pathway.

Authors:  Bercis Imge Ucar; Gulberk Ucar; Sarmistha Saha; Brigitta Buttari; Elisabetta Profumo; Luciano Saso
Journal:  Antioxidants (Basel)       Date:  2021-05-21

Review 6.  Mitochondrial transplantation for therapeutic use.

Authors:  James D McCully; Sidney Levitsky; Pedro J Del Nido; Douglas B Cowan
Journal:  Clin Transl Med       Date:  2016-04-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.